Padesát let časopisu Cor et Vasa

Michael Aschermann

Cor Vasa 2009, 51(1):6-7  

Česká kardiologická společnost v roce 2009

Václav Chaloupka

Cor Vasa 2009, 51(1):8

Deset důvodů, proč se kardiolog musí zajímat o CT vyšetření srdce

Josef Veselka, Theodor Adla

Cor Vasa 2009, 51(1):9-11  

Děkujeme recenzentům

prof. MUDr. Michael Aschermann, DrSc., prof. MUDr. Vladimír Staněk, CSc.

Cor Vasa 2009, 51(1):12  

Effect of secondary prevention on all-cause mortality in Czech survivors of myocardial infarction: a population-based study

Jan Pitha, Ivana Podrapska, Philip H. Frost, Rudolf Poledne, Zdenek Valenta, Richard J. Havel

Cor Vasa 2009, 51(1):13-18 | DOI: 10.33678/cor.2009.006  

Background: In spite of successful introduction of interventional treatment of acute coronary syndromes in Czech Republic, recent surveys show that coronary intervention and drug therapies need to be combined with a lifestyle and risk factor intervention. We assessed the effect of intervention after myocardial infarction targeting multiple risk factors in a high-risk population with limited access to hypolipidemic drugs and revascularization.Methods: In 1992-1993, we enrolled all men under age 60 (n = 68) and all women under age 65 (n = 40) who survived myocardial infarction and were discharged from a single coronary care unit in an 18-month intervention...

Correction of Ebstein's anomaly in the adult patients

Roman Gebauer, Štěpán Černý, Petr Pavel, Bohumil Hučín, Jana Popelová, Pavel Jehlička, Jan Škovránek

Cor Vasa 2009, 51(1):19-23 | DOI: 10.33678/cor.2009.007  

Aim: To evaluate the outcome of correction of Ebstein's anomaly in adult patients undergoing surgery as part of a program of care of adult patients with congenital heart defects.Group of patients/methods: A total of 15 patients with Ebstein's anomaly (age 21-63 years, median 45 years) were operated on from December 2005 through May 2008 at Na Homolce Hospital. In terms of morphology, types A, B, and C were present in three, four, and eight patients, respectively. All patients had significant up to massive tricuspid insufficiency, combined with stenosis in two; eleven patients had arrhythmias (atrial fibrillation or flutter, AV nodal re-entrant...

The pitfalls of echocardiographic evaluation of left ventricular contraction -asynchrony as related to treatment by biventricular pacing

Jaroslav Meluzín, Miroslav Novák, Jolana Lipoldová, Eva Ozábalová

Cor Vasa 2009, 51(1):25-31 | DOI: 10.33678/cor.2009.008  

The aim of the paper is to review the limitations of echocardiographic methods currently employed to demonstrate mechanical left ventricular contraction asynchrony and to identify patients likely to respond to treatment with biventricular pacing. The limitations are serious and may account for the failure of echocardiographic parameters to identify responders to biventricular pacing, as documented in the PROSPECT trial. The paper outlines the complexities of evaluating cardiac contraction asynchrony and discusses the options available for analyzing and assessing it. The authors foresee the use of novel echocardiographic methods and/or parameters (3D...

Inflammatory cardiomyopathy: current concepts regarding its diagnosis and treatment

Petr Kuchynka, Tomáš Paleček, Stanislav Šimek, Ivana Vítková, Jana Schramlová, Dagmar Hulínská, Viktor Aster, Gabriela Dostálová, Sudheera Magage, Michael Aschermann, Aleš Linhart

Cor Vasa 2009, 51(1):32-37 | DOI: 10.33678/cor.2009.009  

Inflammatory cardiomyopathy is a term used for myocarditis associated with left ventricular dysfunction. There are many infectious and non-infectious causes of this disease with viral infection being the most common. In order to definitely establish the diagnosis of inflammatory cardiomyopathy, endomyocardial biopsy (EMB) has to be performed. To obtain appropriate diagnostic information, detailed assessment of EMB including histopathological, immunohistochemical and microbiological evaluation should be performed. The results of EMB specimens processed in such a manner may consequently have an impact on the therapeutic strategy in inflammatory cardiomyopathy,...

Sudden death risk stratification in hypertrophic cardiomyopathy

Stanislava Homolová, David Zemánek, Josef Veselka

Cor Vasa 2009, 51(1):38-40 | DOI: 10.33678/cor.2009.010  

Sudden death is the most serious manifestation of hypertrophic cardiomyopathy (HCM), often occurring as the first presentation of this disease in young and asymptomatic patients. It is for this reason that sudden death risk stratification and prevention play a key role in choosing the therapeutic strategy in the HCM patient. Sudden death risk stratification has gained in importance particularly after obtaining evidence that implantable cardioverter-defibrillator (ICD) implantation is a highly effective method for sudden death prevention. At present, the established risk factors for sudden death include: 1. syncope of unclear etiology, 2. a family history...

Failure of therapy or resistance to antiplatelet drugs?

Hana Ševčíková, Jan Vojáček, Radek Pudil, Josef Šťásek, Josef Bis, Róbert Ševčík, Jaroslav Malý, Petr Dulíček, Miroslav Pecka, Ilona Fátorová

Cor Vasa 2009, 51(1):41-44 | DOI: 10.33678/cor.2009.011  

Even though the efficacy of acetylsalicylic acid (ASA) and clopidogrel has been documented in patients with acute and chronic coronary artery disease (CAD), many patients develop thrombotic cardiovascular complications despite dual anti-platelet therapy due to nonresponsiveness or partial responsiveness. The phenomenon of resistance to antiplatelet therapy remains incompletely defined, influenced as it is by a variety of genetic, cellular, and clinical factors. In conclusion, although clinical guidelines still do not support routine screening for antiplatelet drug resistance (because a standard laboratory assay is still lacking), there is mounting...

Doporučení pro duplexní ultrazvukové vyšetření končetinových žil

Miroslav Vítovec, Václav Pecháček

Cor Vasa 2009, 51(1):55-66 | DOI: 10.33678/cor.2009.016  

Monitoring the dynamics of B-natriuretic peptide may have a major impact on the choice of treatment of the patient with heart failure

Ivan Málek, Markéta Hegarová, Petr Lupínek, Jaroslav Tintěra

Cor Vasa 2009, 51(1):45-48 | DOI: 10.33678/cor.2009.012  

The paper seeks to provide evidence that repeat measurement of serum B-natriuretic peptide levels may contribute to deciding on the therapeutic option to be chosen for the heart failure patient. We report the case of advanced heart failure in a patient with spongiform cardiomyopathy placed urgently on a waiting list for heart transplantation. The ensuing course was unexpectedly favorable and the patient is still being treated conservatively. A decrease in B-natriuretic peptide levels served as an early marker of resolving signs of advanced heart failure.

Do you consider the diagnosis of pulmonary arterial hypertension in elderly patients?

Blanka Kočišková, Yvona Kotroušová, Pavel Jansa

Cor Vasa 2009, 51(1):49-51 | DOI: 10.33678/cor.2009.013  

Pulmonary arterial hypertension (PAH) is generally known to be a hereditary disease; it is believed to develop predominantly in younger individuals. In fact, the diagnosis of PAH is usually established later, when patients are about 41-60 years old. The main reason for the late diagnosis is the non-specific presentation of the disease. Additional reasons may include the short time elapsed from the definition of the diagnosis and the fairly poor therapeutic options available until recently, explaining the shift of detection and treatment of the disease towards elderly patients. It would be a shame not to take the opportunity today when the latest methods...

Recenze

Prof. MUDr. Jan Petrášek, DrSc.

Cor Vasa 2009, 51(1):71-72  

I kriticky nemocný má právo na spojení s okolním světem

Jan Bělohlávek, Ilona Lálová, Vratislav Mrázek, Aleš Linhart

Cor Vasa 2009, 51(1):52 | DOI: 10.33678/cor.2009.014  

Acute Cardiac Care 2008

MUDr. Aleš Tomášek

Cor Vasa 2009, 51(1):70 | DOI: 10.33678/cor.2009.019  

11. symposium PS Chlopenní a vrozené srdeční vady v dospělosti ČKS

Cor Vasa 2009, 51(1):73-80  

Instructions to Authors

Cor Vasa 2009, 51(1):81-82  

Předplatné

Cor Vasa 2009, 51(1):83-84  

Ad multos annos!

Roman Čerbák

Cor Vasa 2009, 51(1):54  

Profesor MUDr. Jan Navrátil, DrSc., doctor honoris causa

Doc. MUDr. Petr Němec, CSc., MUDr. Miroslav Bednařík

Cor Vasa 2009, 51(1):67-68  

Snížení srdeční frekvence při beta-blokádě a kardioprotekce u hypertoniků

Pavel Jerie

Cor Vasa 2009, 51(1):69